Evotec SE (NASDAQ:EVO - Get Free Report)'s share price gapped down prior to trading on Wednesday . The stock had previously closed at $3.64, but opened at $3.54. Evotec shares last traded at $3.55, with a volume of 4,948 shares changing hands.
Evotec Stock Down 0.3 %
The business has a 50-day moving average of $4.14 and a 200-day moving average of $4.10. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99.
Institutional Investors Weigh In On Evotec
Several large investors have recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new stake in Evotec in the 4th quarter valued at $27,000. CSS LLC IL purchased a new stake in shares of Evotec in the fourth quarter valued at about $50,000. Bank of America Corp DE raised its holdings in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after buying an additional 9,289 shares during the last quarter. Lighthouse Investment Partners LLC acquired a new stake in shares of Evotec during the fourth quarter worth about $166,000. Finally, DCF Advisers LLC grew its holdings in shares of Evotec by 5.9% during the fourth quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after buying an additional 12,816 shares during the last quarter. 5.81% of the stock is owned by institutional investors and hedge funds.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
